Literature DB >> 3629749

Effects of castration compared with total androgen blockade on tissue dihydrotestosterone (DHT) concentration in benign prostatic hyperplasia (BPH).

J Geller, J Albert.   

Abstract

We compared the effect of a variety of drug regimens to lower prostate DHT concentration. Patients with BPH were treated for one week prior to surgery with either tamoxifen, flutamide, megestrol acetate, megestrol acetate plus tamoxifen and megestrol acetate plus DES or ketoconazole. DHT concentration in the surgically resected tissue was compared with tissues obtained from untreated patients. We also obtained prostate tissue at the time of relapse in patients with prostate cancer who had been treated with orchiectomy with or without estrogen therapy. Megestrol acetate plus the mini-dose of DES (0.1 mg) and megestrol acetate plus ketoconazole both decreased DHT concentrations in prostate tissue to levels (0.79 ng/g) significantly below those noted with orchiectomy (1.16 ng/g). The difference between the DHT concentration in the two groups (orchiectomy vs. total androgen blockade) represents the contribution of adrenal androgens to prostate tissue DHT. This small amount of DHT (approximately 0.4 ng/g) may be biologically important in stimulating prostate epithelial cell growth.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3629749     DOI: 10.1007/BF00254427

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  8 in total

1.  DHT concentrations in human prostate cancer tissue.

Authors:  J Geller; J Albert; D Loza; S Geller; W Stoeltzing; D de la Vega
Journal:  J Clin Endocrinol Metab       Date:  1978-03       Impact factor: 5.958

2.  Ketoconazole in the management of precocious puberty not responsive to LHRH-analogue therapy.

Authors:  F J Holland; L Fishman; J D Bailey; A T Fazekas
Journal:  N Engl J Med       Date:  1985-04-18       Impact factor: 91.245

3.  Acute effects of testicular and adrenal cortical blockade on protein synthesis and dihydrotestosterone content of human prostate tissue.

Authors:  J Liu; J Geller; J Albert; M Kirshner
Journal:  J Clin Endocrinol Metab       Date:  1985-07       Impact factor: 5.958

4.  Regulation and compartmentalization of androgens in rat prostate and muscle.

Authors:  W Bartsch; C Knabbe; K D Voigt
Journal:  J Steroid Biochem       Date:  1983-07       Impact factor: 4.292

5.  Comparison of various hormonal therapies for prostatic carcinoma.

Authors:  J Geller; J D Albert
Journal:  Semin Oncol       Date:  1983-12       Impact factor: 4.929

Review 6.  Adrenal androgen blockade in relapsed prostate cancer.

Authors:  J Geller; J D Albert
Journal:  Eur J Cancer Clin Oncol       Date:  1985-10

7.  Characterization of the cytosol androgen receptor of the human prostate.

Authors:  D M Wilbert; J E Griffin; J D Wilson
Journal:  J Clin Endocrinol Metab       Date:  1983-01       Impact factor: 5.958

8.  Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy.

Authors:  J Geller; J D Albert; D A Nachtsheim; D Loza
Journal:  J Urol       Date:  1984-10       Impact factor: 7.450

  8 in total
  8 in total

Review 1.  Review of assessment of total androgen blockade as treatment of metastatic prostate cancer.

Authors:  J Geller
Journal:  J Endocrinol Invest       Date:  1991-11       Impact factor: 4.256

Review 2.  Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy.

Authors:  Changmeng Cai; Steven P Balk
Journal:  Endocr Relat Cancer       Date:  2011-08-30       Impact factor: 5.678

3.  Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: a randomized, controlled trial.

Authors:  Elahe A Mostaghel; Daniel W Lin; John K Amory; Jonathan L Wright; Brett T Marck; Peter S Nelson; Alvin M Matsumoto; William J Bremner; Stephanie T Page
Journal:  J Clin Endocrinol Metab       Date:  2012-06-01       Impact factor: 5.958

4.  Pharmacia Award 1990. The biological significance of low testosterone levels and of adrenal androgens in transplantable prostate cancer lines.

Authors:  W M van Weerden; A van Kreuningen; E P Moerings; F H de Jong; G J van Steenbrugge; F H Schröder
Journal:  Urol Res       Date:  1991

Review 5.  Mechanisms mediating androgen receptor reactivation after castration.

Authors:  Xin Yuan; Steven P Balk
Journal:  Urol Oncol       Date:  2009 Jan-Feb       Impact factor: 3.498

Review 6.  Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.

Authors:  X Yuan; C Cai; S Chen; S Chen; Z Yu; S P Balk
Journal:  Oncogene       Date:  2013-06-10       Impact factor: 9.867

7.  Steroid hormone synthetic pathways in prostate cancer.

Authors:  Elahe A Mostaghel
Journal:  Transl Androl Urol       Date:  2013-09

8.  Patient-derived tissue slice grafts accurately depict response of high-risk primary prostate cancer to androgen deprivation therapy.

Authors:  Hongjuan Zhao; Alan Thong; Rosalie Nolley; Stephen W Reese; Jennifer Santos; Alexandre Ingels; Donna M Peehl
Journal:  J Transl Med       Date:  2013-08-28       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.